English

JuveLook Import for Clinics: Authentic Product Procurement & Nodule Risk Management | TASAKI PHAMA

What is Juvelook? A New Option for Skin Rejuvenation Therapy

In recent years, the concept of “skin rejuvenation,” which enhances the skin’s natural regenerative abilities, has been gaining attention in the field of aesthetic medicine. Among these, Juvelook is an injectable that combines Poly Lactic Acid (PLA) and non-crosslinked hyaluronic acid, offering a wide range of benefits, including improved skin firmness and elasticity, reduced pore size, and acne scar improvement.

Juvelook stimulates collagen production by injecting it into the dermis layer, enhancing the skin’s self-renewal capabilities. Unlike traditional hyaluronic acid injections, Juvelook gradually promotes collagen production as it decomposes, resulting in natural volume enhancement and long-term skin quality improvement.

A similar formulation to Juvelook is Lenisna, which also contains polylactic acid as its main ingredient. Lenisna also promotes collagen production, but it has a larger particle size compared to Juvelook, resulting in a greater volumizing effect. The choice of which formulation to use depends on the patient’s skin condition and desired results.

What Medical Institutions Should Know When Considering Juvelook Implementation

Medical institutions considering implementing Juvelook should consider the following points:

  • Selection of Suitable Patients: Juvelook is expected to be effective for patients concerned about decreased skin firmness and elasticity, enlarged pores, and acne scars. However, it is necessary to thoroughly check the patient’s skin condition and any allergies, and carefully determine the suitability.
  • Acquisition of Appropriate Injection Techniques: Acquiring appropriate injection techniques is essential to maximize the effects of Juvelook and minimize the risk of side effects. It is important to actively participate in seminars and training sessions organized by manufacturers and strive to improve techniques.
  • Complications and Their Management: Complications after Juvelook injection include swelling, redness, and bruising at the injection site. These symptoms usually improve naturally within a few days to a week, but symptoms can be alleviated with proper aftercare. Rarely, there have been reports of nodule formation. To avoid the risk of nodule formation, it is important to dissolve the product at the appropriate concentration and inject it evenly.
  • Sufficient Explanation to Patients: It is important to fully explain the effects, risks, and downtime of Juvelook to patients and obtain their consent. Be sure to provide careful counseling so that patients can receive treatment with peace of mind.

Authentic Juvelook Import and Quality Control: TASAKI PHARMA’s Initiatives

While Juvelook is highly popular in the field of aesthetic medicine, unfortunately, counterfeit and substandard products are also in circulation. These products are not guaranteed in terms of quality and safety and may cause health damage to patients.

We (TASAKI PHARMA) provide authentic import agency services so that medical institutions can introduce Juvelook with confidence. We have direct contracts with reliable overseas manufacturers and import products under a strict quality control system. We also pay close attention to temperature control and quality maintenance during product storage and transportation.

The Juvelook introduction set we provide includes the following:

  • Juvelook main unit
  • Dissolution liquid
  • Instruments required for injection (syringes, needles, etc.)
  • Treatment manual
  • Explanatory materials for patients

The introduction set includes everything needed for Juvelook treatment, allowing for a smooth introduction. In addition, the treatment manual and explanatory materials for patients were created based on our many years of experience and provide detailed explanations of the effective use and precautions of Juvelook.

Nodule Risk and Countermeasures with Juvelook

There have been rare reports of nodule formation after Juvelook injection. The causes of nodule formation include the following:

  • Insufficient dissolution of the drug
  • Inappropriate concentration during injection
  • Unevenness in the injection site
  • Insufficient massage after injection

It is important to take the following measures to minimize the risk of nodule formation:

  • When dissolving the drug, follow the manufacturer’s recommended method and dissolve it thoroughly over time.
  • The concentration at the time of injection should be the concentration recommended by the manufacturer.
  • Inject evenly so that there is no unevenness in the injection site.
  • After injection, perform appropriate massage according to the doctor’s instructions.

If a nodule forms, it is important to consult a doctor immediately and receive appropriate treatment. If the nodule is small, it may be improved with massage or thermotherapy, but if it is large, hyaluronidase injection or surgical excision may be necessary.

Juvelook is a formulation that can provide safe and effective skin rejuvenation treatment if used with appropriate knowledge and technology. Medical institutions should collect sufficient information and prepare thoroughly when introducing Juvelook, and strive to ensure that patients can receive treatment with peace of mind.

Summary

Juvelook is an injectable that combines polylactic acid and hyaluronic acid, promotes collagen production in the skin, and has the potential to contribute to improving skin firmness, elasticity, pores, and acne scars. It is a new option in aesthetic medicine. When introducing it, it is essential to select authentic products, acquire appropriate techniques, and provide careful information to patients. In particular, understanding the risk of nodule formation and taking appropriate measures can provide safer and more effective treatment. The progress of aesthetic medicine is remarkable, and the emergence of innovative formulations such as Juvelook has the potential to contribute to improving patients’ QOL.